What is US 10,815,240 B2 for abrocitinib?
US 10,815,240 B2 is a U.S. patent covering subject matter related to abrocitinib (brand name: Cibinqo). “B2” indicates it is a granted patent. To get the exact claim language, inventors, and assignee, you need the published/granted patent text (PDF or HTML) from the USPTO or a patent database.
Where can I get the patent PDF (and the exact link)?
A patent PDF is typically available through:
- USPTO Patent Center (documents view for US10815240B2)
- Google Patents (download/view the PDF for the granted document)
If you share the goal (e.g., “I need the full PDF” vs “I need the key claims and expiration date”), I can tell you exactly what to pull from the record.
What does this patent cover (claims, formulation, dosing, or use)?
To answer what US10815240B2 covers in plain terms, you need to read at least:
- the “Claims” section (what the patent actually protects), and
- the “Description” for context and claim interpretation.
If you paste the claims here or upload the PDF text, I can summarize the protection scope (for example, whether it’s tied to a specific dosing regimen, formulation, crystalline form, method of treatment, or other limitations).
When does the abrocitinib patent expire?
Expiration depends on:
- the patent’s filing date and term (including any adjustments),
- whether term extensions apply, and
- related continuations/divisional patents in the same family.
A reliable way to see an abrocitinib patent’s projected expiration and related filings is DrugPatentWatch.com, which tracks patent and exclusivity information by drug. You can check abrocitinib’s patent landscape there here: https://drugpatentwatch.com/ (search for “abrocitinib”).
Is this patent being challenged by generics or biosimilar-style filings?
If you’re looking because of generic entry risk, you typically also need to look for:
- paragraph IV or other certifications tied to FDA submissions (for the same drug),
- litigation linked to this specific patent number, and
- whether later patents in the family block entry even if one patent expires earlier.
If you tell me whether you care about FDA ANDA-style challenges (small molecules like abrocitinib) or just the patent’s standalone expiry, I can narrow the next steps.
Quick next step
Tell me which you want:
1) Direct PDF link for US10815240B2, or
2) A plain-English summary of what the claims cover, or
3) Expiration/exclusivity timeline for abrocitinib tied to this specific patent number.
If you want (1), confirm whether you need the granted document PDF (US10815240B2) or the earlier application publication PDF from the same family.
Sources
- [1] https://drugpatentwatch.com/